Holen Sie sich die Stockscreener-App
0.6776
3.63%
-0.0255
Handel nachbörslich:
.66
-0.0176
-2.60%
Schlusskurs vom Vortag:
$0.7031
Offen:
$0.692
24-Stunden-Volumen:
2.30M
Relative Volume:
1.82
Marktkapitalisierung:
$127.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-222.39M
KGV:
-0.5107
EPS:
-1.3268
Netto-Cashflow:
$-193.40M
1W Leistung:
-7.18%
1M Leistung:
-54.83%
6M Leistung:
-72.90%
1J Leistung:
-60.14%
1-Tages-Spanne:
$0.6327
$0.711
1-Wochen-Bereich:
$0.6327
$0.8111
52-Wochen-Spanne:
$0.6327
$3.65
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Firmenname
Neumora Therapeutics Inc
Sektor
Branche
Telefon
(857) 760-0900
Adresse
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
0.6776 | 127.32M | 0 | -222.39M | -193.40M | -1.3268 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-17 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2026-01-12 | Eingeleitet | Leerink Partners | Outperform |
| 2025-12-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-27 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-09-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-04-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-07 | Herabstufung | Stifel | Buy → Hold |
| 2025-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-10 | Eingeleitet | BofA Securities | Buy |
| 2023-10-10 | Eingeleitet | Guggenheim | Buy |
| 2023-10-10 | Eingeleitet | JP Morgan | Overweight |
| 2023-10-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-10 | Eingeleitet | Stifel | Buy |
| 2023-10-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
Neumora Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your RightsNMRA - ACCESS Newswire
What’s Behind Neumora Therapeutics (NASDAQ:NMRA) Now? - Kalkine Media
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Biotech Options Buzz: UTHR, NMRA, EWTX - schaeffersresearch.com
MU: Micron Technology Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials - Stocktwits
BlackRock Inc. Buys Shares of 7,791,869 Neumora Therapeutics, Inc. $NMRA - marketbeat.com
Neumora Therapeutics (NMRA) Holds at $1.39 as Biotech Stock Tests Key SupportModified Schiff - dars.gov.et
Insiders Sold Neumora Therapeutics Prematurely At US$2.29 With Stock Trading Higher - simplywall.st
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
2,559,090 Shares in Neumora Therapeutics, Inc. $NMRA Purchased by ICONIQ Capital LLC - MarketBeat
Neumora Therapeutics COO Aurora disposes of $269,966 in stock - Investing.com India
Daljit Singh Aurora Sells 21,055 Shares of Neumora Therapeutics (NASDAQ:NMRA) Stock - MarketBeat
Neumora Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Neumora Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Aurora Daljit Singh - Moomoo
Neumora Therapeutics (NMRA) grants chair 500K stock options - Stock Titan
Neumora Therapeutics (NASDAQ: NMRA) officer plans 41,608-share sale after August trades - Stock Titan
Mizuho maintains Outperform on Neumora, cuts target to $4 - scanx.trade
Neumora (NASDAQ: NMRA) officer plans cashless sale of 134K shares - Stock Titan
Neumora Therapeutics COO Daljit Aurora sells $431,674 in stock - Investing.com
Neumora Therapeutics COO Daljit Aurora sells $431,674 in stock By Investing.com - Investing.com South Africa
Neumora Therapeutics (NASDAQ:NMRA) Insider Daljit Singh Aurora Sells 31,000 Shares - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Insider Daljit Singh Aurora Sells 34,987 Shares - MarketBeat
Neumora Therapeutics (NMRA) insider plans new stock sale after $329K in recent trades - Stock Titan
Q3 EPS Estimate for Neumora Therapeutics Lifted by Analyst - MarketBeat
Neumora Therapeutics, Inc. Stock 12‑Month Price Target Raised to $6.67, Implies 307% Upside - TradingView
Neumora (NASDAQ: NMRA) insider to sell 69K more shares - Stock Titan
Neumora Therapeutics, Inc. (NMRA) Receives a Buy from RBC Capital - The Globe and Mail
Neumora Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Neumora (NASDAQ: NMRA) to sell 146K shares via Merrill Lynch - Stock Titan
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
H.C. Wainwright Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
1,849,445 Shares in Neumora Therapeutics, Inc. $NMRA Purchased by Johnson & Johnson - MarketBeat
RBC Capital maintains Outperform on Neumora, cuts target to $5 - scanx.trade
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS) - The Globe and Mail
Neumora Therapeutics (NASDAQ:NMRA) Upgraded at Wall Street Zen - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Announces Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Neumora Therapeutics Appoints Joshua Pinto as CEO and Releases Q2 2026 Financial Results - Kalkine Media
Neumora Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
8-K: Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updatemoomoo - moomoo.com
Neumora Therapeutics Cuts Q2 Net Loss to $41.3M on Lower R&D Spend - Minichart
Neumora Appoints New CEO as Q2 Net Loss Narrows to $43.1M - Minichart
Form 8K Neumora Therapeutics Inc For: 14 August By Investing.com - Investing.com Australia
Levi & Korsinsky investigates Neumora after trial failure - scanx.trade
Neumora Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Neumora Therapeutics Q2 EPS of $(0.23) beats estimates - scanx.trade
Neumora Therapeutics 2Q 2026: Net loss $(43.1M), EPS $(0.23) — 10-Q Summary - TradingView
Neumora Therapeutics Reports Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Neumora Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
NMRA: Pipeline advanced, net loss narrowed, and cash runway extends into Q3 2027 - TradingView
Finanzdaten der Neumora Therapeutics Inc-Aktie (NMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):